Evolus (NASDAQ:EOLS) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Evolus (NASDAQ:EOLS) in a research report released on Monday, Benzinga reports.

Other analysts also recently issued reports about the company. Needham & Company LLC restated a buy rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, August 1st. HC Wainwright reaffirmed a buy rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, August 1st.

Evolus Price Performance

Shares of EOLS stock opened at $15.27 on Monday. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. Evolus has a twelve month low of $7.44 and a twelve month high of $16.29. The company has a market cap of $963.38 million, a P/E ratio of -14.54 and a beta of 1.30. The business has a fifty day simple moving average of $13.44 and a 200 day simple moving average of $13.00.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, sell-side analysts forecast that Evolus will post -0.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC increased its stake in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after buying an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after buying an additional 930,566 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Evolus in the first quarter valued at about $11,628,000. BNP Paribas Financial Markets boosted its position in shares of Evolus by 84.2% during the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after purchasing an additional 185,532 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Evolus during the 2nd quarter valued at about $3,906,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.